Role of semiquantitative assessment of regional binding potential in 123I-FP-CIT SPECT for the differentiation of frontotemporal dementia, dementia with Lewy bodies, and Alzheimer's dementia

Clinical Nuclear Medicine

Volumn 40, Issue 1, 2014, Pages e27-e33

  Spehl, Timo S ^a   Frings, Lars ^a   Hellwig, Sabine ^a   Weiller, Cornelius ^a   Hüll, Michael ^a   Meyer, Philipp T ^a   Amtage, Florian ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

123I FP CIT SPECT; Alzheimer disease; Dementia with Lewy bodies; Frontotemporal dementia

Indexed keywords

N U FLUOROPROPYL 2B CARBOMETHOXY 3B (4 IODOPHENYL)NORTROPANE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; TROPANE DERIVATIVE; N U FLUOROPROPYL 2B CARBOMETHOXY 3B(4 IODOPHENYL)NORTROPANE I 123;

ADULT; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; FEMALE; FRONTOTEMPORAL DEMENTIA; GLUCOSE METABOLISM; HUMAN; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; AGED; ANTIBODY SPECIFICITY; DIAGNOSTIC USE; DIFFERENTIAL DIAGNOSIS; EVALUATION STUDY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BRAIN ASYMMETRY; BRAIN SCINTISCANNING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; PUTAMEN;

AGED; ALZHEIMER DISEASE; DIAGNOSIS, DIFFERENTIAL; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84906001764     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000554     Document Type: Article

References (48)

1. Seelaar H, Rohrer JD, Pijnenburg YA, et al. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82:476-486.
2. Sieben A, van Langenhove T, Engelborghs S, et al. The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol. 2012;124: 353-372.
3. Ratnavalli E, Brayne C, Dawson K, et al. The prevalence of frontotemporal dementia. Neurology. 2002;58:1615-1621.
4. Josephs KA, Hodges JR, Snowden JS, et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 2011;122:137-153.
5. Boxer AL, Knopman DS, Kaufer DI, et al. Mematine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013:12:149-156.
6. 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. J Nucl Med. 2005;46:233-239.
7. 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008;49:390-398.
8. Mackenzie IRA, Baker M, Pickering-Brown S, et al. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain. 2006;129:3081-3090.
9. Espay AJ, Litvan I. Parkinsonism and frontotemporal dementia: the clinical overlap. J Mol Neurosci. 2011;45:343-349.
10. Le Ber I, Camuzat A, Hannequin D, et al. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain. 2008;131:732-746.
11. Diehl-Schmid J, Schūlte-Overberg J, Hartmann J, et al. Extrapyramidal signs, primitive reflexes and incontinence in fronto-temporal dementia. Eur J Neurol. 2007;14:860-864.
12. Rinne JO, Laine M, Kaasinen V, et al. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology. 2002;58:1489-1493.
13. Sedaghat F, Gotzamani-Psarrakou A, Dedousi E, et al. Evaluation of dopaminergic function in frontotemporal dementia using I-FP-CIT single photon emission computed tomography. Neurodegener Dis. 2007;4:382-385.
14. Johnson JK, Head E, Kim R, et al. Clinical and pathological evidence for a frontal variant of alzheimer disease. Arch Neurol. 1999;56:1233-1239.
15. Claassen DO, Parisi JE, Giannini C, et al. Frontotemporal dementia mimicking dementia with Lewy bodies. Cogn Behav Neurol. 2008;21:157-163.
16. Aries MJH, Le Bastard N, Debruyne H, et al. Relation between frontal lobe symptoms and dementia severity within and across diagnostic dementia categories. Int J Geriatr Psychiatry. 2010;25:1186-1195.
17. Walker Z, Jaros E, Walker RWH, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78:1176-1181.
18. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with I-123-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305-313.
19. Morgan S, Kemp P, Booij J, et al. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry. 2012;83:1063-1070.
20. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62:133-140.
21. Tissingh G, Booij J, Bergmans P, et al. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med. 1998;39: 1143-1148.
22. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539.
23. 123I-2-β-carbomethoxy-3β-(4-Iodophenyl)-N-(3-fluoropropyl)nortropane SPECT studies. J Nucl Med. 2013;54:714-722.
24. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
25. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863-1872.
26. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554.
27. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1-9.
28. Litvan I, Bhatia KP, Burn DJ, et al. SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003;18:467-486.
29. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670-676.
30. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol. 2003;54(suppl 5):15-19.
31. Minoshima S, Frey KA, Koeppe RA, et al. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238-1248.
32. Hellwig S, Amtage F, Kreft A, et al. (18)F-FDG-PET is superior to (123)I-IBZMSPECT for the differential diagnosis of parkinsonism. Neurology. 2012;79: 1314-1322.
33. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005;26:912-921.
34. Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 2010;9: 149-158.
35. Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using I-123-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443-450.
36. Winz OH, Hellwig S, Mix M, et al. Image quality and data quantification in dopamine transporter SPECT: advantage of 3-dimensional OSEM reconstruction. Clin Nucl Med. 2012;37:866-871.
37. Mendez MF, Shapira JS, McMurtray A, et al. Accuracy of the clinical evaluation for frontotemporal dementia. Arch Neurol. 2007;64:830-835.
38. Gil-Navarro S, Lomena F, Cot A, et al. Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia. Eur J Neurol. 2013;20:1459-e126.
39. Mann DM, South PW, Snowden JS, et al. Dementia of frontal lobe type: neuropathology and immunohistochemistry. J Neurol Neurosurg Psychiatry. 1993;56:605-614.
40. Burke JF, Albin RL, Koeppe RA, et al. Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain. 2011;134:1647-1657.
41. 11C]-βCFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology. 1998;50:152-156.
42. Rinne JO, Ruottinen H, Bergman J, et al. Usefulness of a dopamine transporter PET ligand [(18)F]β-CFT in assessing disability in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999;67:737-741.
43. Antonini A, Benti R, Notaris R de, et al. I-123-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinsons disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci. 2003;24:149-150.
44. Walker Z, Costa DC, Walker RWH, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology. 2004;62:1568-1572.
45. Minoshima S, Foster NL, Sima AA, et al. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50:358-365.
46. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing Frontotemporal dementia and Alzheimer's disease. Brain. 2007;130:2616-2635.
47. Ling H, O'Sullivan SS, Holton JL, et al. Does cortico-basal degeneration exist? A clinicopathological re-evaluation. Brain. 2010;133:2045-2057.
48. Pasquier F, Lebert F, Lavenu I, et al. The clinical picture of frontotemporal dementia: diagnosis and follow-up. Dement Geriatr Cogn Disord. 1999; 10:10-14.